Semaglutide 8mg Injection Pen Kit
£149.99
The Synedica Semaglutide® Injection Pen Kit is a clinically advanced treatment for weight loss. Known commonly as Ozempic, semaglutide works by mimicking the natural hormone GLP-1, which signals to your brain that you are full after eating. By reducing appetite and cravings, it supports significant and sustainable weight loss.
What does the 1mg Kit Contain?
-
2 × Synedica semaglutide pens (each containing 4mg)
-
12 × disposable 32g 4mm needles
-
1 × instruction booklet
Each pen delivers up to 4 full doses of 1mg or smaller increments of 0.25mg, 0.5mg, 0.75mg, or 1mg, depending on your prescribed dosage.
Recommended Dosage Schedule:
-
Weeks 1–4: 0.25mg once weekly
-
Weeks 5–8: 0.5mg once weekly
-
After 8 weeks: Your doctor may increase to 0.75mg or 1mg once weekly
Buy Semaglutide UK
What is the Synedica Semaglutide® Injection Pen Kit?
The Synedica Semaglutide® Injection Pen Kit is one of the world’s most advanced medical weight loss solutions. Containing semaglutide (commonly known as Ozempic), it works by mimicking the hormone GLP-1 to suppress appetite, helping you feel fuller after smaller meals. A single kit typically lasts 12 weeks for new users.
Key Benefits:
-
Reduces appetite and cravings throughout the day
-
Supports significant and sustainable fat loss
-
Helps avoid the hunger pangs of traditional dieting
Common Side Effects:
Mild to moderate side effects may include nausea, jaw ache, and low mood. A complete list of potential side effects can be found in the included patient information booklet.
What’s Included in Each Kit:
-
2 × Synedica semaglutide pens
-
12 × disposable 32g 4mm needles
-
1 × instruction booklet
Cost & Availability:
-
Typical cost: €300 per kit (12 weeks supply) from private pharmacies
-
May be covered by employer health policies or available to eligible patients in Germany through Gesetzliche Krankenversicherung (GKV)
-
Currently available by prescription only in Germany
Synedica vs Other GLP-1 Medications:
-
Semaglutide (Synedica/Ozempic): First-line treatment, targeting 1 receptor (GLP-1)
-
Tirzepatide: Second-line option for patients with semaglutide tolerance; targets 2 receptors for greater effect at lower doses
-
Retatrutide: Newest triple-agonist, targeting 3 receptors, ideal for patients who have developed tolerance to tirzepatide
MAECENAS IACULIS
Vestibulum curae torquent diam diam commodo parturient penatibus nunc dui adipiscing convallis bulum parturient suspendisse parturient a.Parturient in parturient scelerisque nibh lectus quam a natoque adipiscing a vestibulum hendrerit et pharetra fames nunc natoque dui.
ADIPISCING CONVALLIS BULUM
- Vestibulum penatibus nunc dui adipiscing convallis bulum parturient suspendisse.
- Abitur parturient praesent lectus quam a natoque adipiscing a vestibulum hendre.
- Diam parturient dictumst parturient scelerisque nibh lectus.
Scelerisque adipiscing bibendum sem vestibulum et in a a a purus lectus faucibus lobortis tincidunt purus lectus nisl class eros.Condimentum a et ullamcorper dictumst mus et tristique elementum nam inceptos hac parturient scelerisque vestibulum amet elit ut volutpat.
